New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 9, 2018 - Theravance Biopharma and Mylan announced the FDA approval Yupelri (revefenacin), for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Download PDF
Return to publications
